The Lancet Oncology
@TheLancetOncol
Followers
59K
Following
1K
Media
2K
Statuses
10K
The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=41.6
Joined June 2009
🆕 Our May issue is now live: 📊 Original research on #colorectalcancer, #renalcellcarcinoma, #prostatecancer, #lungcancer, #AMR, #breastcancer, and #melanoma. 📖Reviews include AMR in patients with #haematologicalmalignancies and optimal use of drugs
0
4
16
37
666
416
Good illustration of progress in cancer control, albeit with some notable exceptions.
16
306
373
NEW global study estimates that 4% (741,000 cases) of new #cancer cases in 2020 may be associated with drinking #alcohol Read: .#OpenAccess @IARCWHO
2
131
188
Online first: #Doxorubicin alone versus doxorubicin with #trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable #leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
1
62
152
3
101
160
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer #crcsm
0
70
154
Presented at #SABCS24:. Interim results from the EUROPA trial:. Single-modality #endocrinetherapy vs #radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early #breastcancer.
3
79
152
Online first: #Larotrectinib in patients with TRK fusion-positive solid #tumours: a pooled analysis of three phase 1/2 #clinicaltrials
3
84
147
“The fact that being overweight or obese is related to many cancers. adds urgency to the issue of the world's expanding waist line’’ @MichaelMarmot on the new @wcrfint #cancerprevention report #healthandcancer
5
100
117
Are you presenting your research in an oral session at #SABCS21 in December? Submit your manuscript by Oct 5 to be eligible for potential coordinated publication with your presentation.
3
9
110
New Review in our July issue: Pressurised #intraperitoneal #aerosol #chemotherapy: rationale, evidence, and potential indications
1
60
110
On #WorldCancerDay, we’re focusing on the major burden of #cancer in #children and #AYAs and making a collection of papers free to read with registration (also free)
1
67
96
NEW online: SOC-1 trial—Secondary #cytoreduction followed by #chemotherapy versus chemotherapy alone in platinum-sensitive relapsed #ovariancancer #surgery #gyncsm
4
46
104
New Article online: Use of #prostate systematic and targeted #biopsy on the basis of multiparametric #MRI in biopsy-naive patients—the paired #diagnostic MRI-FIRST study
6
81
101
Now live: Our new #PalOnc Commission proposes that integration of #palliativecare within #oncology care pathways must be anchored into international and national #cancer plans by management and policy makers and be adequately funded #ESMO2018
2
62
90
Article Online: Optimal #sequencing of #enzalutamide and #abiraterone acetate plus #prednisone in metastatic castration-resistant #prostatecancer: a randomised, open-label, phase 2 crossover trial
2
54
97
New ONLINE: CATNON, EORTC study 26053-22054 – Adjuvant and concurrent #temozolomide for 1p/19q non-co-deleted anaplastic #glioma: second interim analysis of a randomised, open-label, phase 3 study. #btsm .
2
49
93
Very sad day for Americans and the world, a calamity: Trump orders US to leave World Health Organization
6
50
96
NEW Research: #Safety and #immunogenicity of one versus two doses of the #COVID19 #vaccine BNT162b2 for patients with #cancer: interim analysis of a prospective observational study
1
54
93
Review: Characterisation & classification of #oligometastatic disease: a @ESTRO_RT and @EORTC consensus recommendation
1
70
90
Online first: phase 3 study of second-look #surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs surveillance in patients at high risk of developing colorectal peritoneal metastases—PROPHYLOCHIP–PRODIGE 15
1
56
86
NEW online: Intermediate clinical #endpoints for #surrogacy in localised #prostatecancer: an aggregate meta-analysis #pcsm
2
46
81
Presented at #ASTRO19 and now online @TheLancetOncol: acute toxicity results from the PACE-B trial on intensity-modulated fractionated #radiotherapy vs stereotactic body radiotherapy for #prostatecancer
0
49
75
Tonight (2330 h GMT), we publish the next milestone report of @TheLancet's #FutureChild Campaign. A new @TheLancetOncol Commission synthesises evidence to show how millions of children’s lives could be saved with investment in cancer treatments & health systems #ChildhoodCancer
1
39
73
New online: PRODIGE 7 - #Cytoreductive #surgery plus hyperthermic intraperitoneal chemotherapy #HIPEC versus cytoreductive surgery alone for colorectal peritoneal metastases
0
35
73
NOW OF: 5-year survival endpoints from the VESPER phase 3 RCT of perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer.
1
28
72
Our new AUGUST issue has articles on #braintumours, #alcohol & #cancer, #prostatecancer, #pancreaticcancer, #thyroidcancer, #breastcancer and much more. Read it here:
2
20
68
NEW Comment on #COVID19 #vaccine side-effects in patients with #cancer undergoing active treatment with #immunecheckpointinhibitor therapy.
1
33
68
New Comment: The official French guidelines to protect patients with cancer against SARS-CoV-2 infection .#COVID19
2
54
65
Presented at #ESMO24 and published simultaneously @TheLancetOncol: The randomised ph2 UpFrontPSMA study: . Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive #prostatecancer
0
29
67
New Editorial: Racism, discrimination, and the practice of oncology
6
27
66
Online first: #Neoadjuvant #durvalumab with or without stereotactic body #radiotherapy in patients with early-stage non-small-cell #lungcancer: a single-centre, randomised phase 2 trial.#NSCLC #lcsm.
0
39
68
On #WHPCDay18, we announce a new Commission on integrating #oncology and #palliativecare, which will launch next week at #ESMO2018 @myESMO. Follow #PalOnc @Oslounivsykehus @PRC_Palliation @UniOslo_MED
0
34
61
Approximately 90% of children with cancer live in low-income and middle-income countries (LMICs), where 5-year survival can be lower than 20%.
2
42
65
1
81
64
NOW OF: In the final 10-yr survival analysis of the OVHIPEC-1 ph 3 RCT of cytoreductive surgery w/o vs w/ HIPEC in pts with adv ovarian cancer, median PFS was 10·7 months (95% CI 9·6–12·0) vs 14·3 months (12·0–18·5); HR 0·63 [95% CI 0·48–0·83], p=0·0008).
0
47
68
New research: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for #oesophagealcancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.
0
32
65
Also NEW online: Stereotactic ablative #radiotherapy (SABR) for operable stage I non-small-cell #lungcancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery
0
29
63
Online first: #Dabrafenib plus #trametinib in patients with BRAFV600E-mutated #biliarytract #cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
1
20
53
Read the #Cancer #Survivorship in the #USA Series of 5 papers here: #patients #primarycare #psychosocial #challenges
2
40
53
Our first issue of 2022 is now live! .Read it here: .This issue has articles on #AYAcancer, #myeloma, immune checkpoint inhibitors, #lungcancer #radiotherapy & #screening, #hepatocellularcarcinoma, #breastcancer and much more
1
28
59
0
34
54
Today on #WorldCancerDay , our Editor-in-Chief David Collingridge moderated an interagency panel discussion at WHO on the upcoming WHO Global #BreastCancer Initiative – a global collaborative effort between @WHO, @IARCWHO, @iaeaorg, and other partners from various sectors
3
13
56
Online first: 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after #prostatectomy: a prospective comparative #imaging trial
1
34
58
Now online: randomised controlled #clinicaltrial of early and systematic integration of #palliativecare in patients with advanced #cancer
1
61
54
Also OF: . 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant #prostatecancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
1
20
58
Day 1 of #2018WCC #CancerCongress. Session by Dutch Cancer Society on access to affordable medicines. This slide says it all.
1
33
56
Online first: the phase 3 STRASS trial (@EORTC-62092) - #Preoperative #radiotherapy plus #surgery vs surgery alone for patients with primary retroperitoneal #sarcoma
1
39
57
NOW OF: In interim analysis of the KEYNOTE-585 ph 3 trial, neoadjuvant and adjuvant pembrolizumab improved pathological complete response versus placebo but not event-free survival in patients with locally advanced gastric or gastro-oesophageal cancer.
1
16
55
New Research: Recurrence-free #survival versus overall survival as a primary #endpoint for studies of resected #colorectal #liver #metastasis: a retrospective study and meta-analysis
1
25
54
New Article online: phase 3 trial of #stereotactic ablative #radiotherapy versus standard radiotherapy in stage 1 non-small-cell #lungcancer #NSCLC—the TROG 09.02 CHISEL study
0
40
51
Launching NOW at #ECR2021 @myESR—new @TheLancetOncol Commission on #MedicalImaging and #NuclearMedicine:
3
22
54
Online first: #ArtificialIntelligence for #diagnosis and grading of #prostatecancer in biopsies: a population-based, diagnostic study
1
36
53
Online first: extended follow-up of the phase 3 KEYNOTE-426 trial: #Pembrolizumab plus #axitinib vs #sunitinib as first-line treatment of advanced #renalcellcarcinoma .#kcsm
1
23
53
Online first: Androgen deprivation therapy use and duration with definitive #radiotherapy for localised #prostatecancer: an individual patient data meta-analysis
1
21
51
Congrats to #PresidentElect @JoeBiden and #VPElect @KamalaHarris on their historic win. We look forward to a reinvigorated Cancer Moonshot programme & thank @JoeBiden for his support of our #FutureCancerUSA Commission
0
7
51
Online first: phase 3 Lung ART trial - #postoperative #radiotherapy (#PORT) vs no PORT in patients with completely resected #NSCLC & proven mediastinal N2 involvement .#lungcancer #lcsm.
3
22
52
Our new NOVEMBER issue has articles on #prostatecancer, #HPVvaccination, gestational trophoblastic neoplasia, #lungcancer, #haemonc, #cancer #surgery during #COVID, #biliarytractcancer & much more. Read it here:
1
17
48
NOW OF: Essay—Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer. Read the Authors' reply here:.
1
18
51
Presenting now at #ESMO21: Extended therapy with #letrozole as #adjuvant treatment of postmenopausal patients with early-stage #breastcancer: a multicentre, open-label, randomised, phase 3 trial.#bcsm @myESMO .
1
22
51
Our January issue is now live!. Including studies in urothelial carcinoma, cervical, breast, and prostate cancers, PTCL, colorectal liver metastases, TRAEs, and cancer mortality; reviews in RCC and gliomas; a UK National Cancer Plan; and much more.
5
18
51
NOW OF: The (DARS) phase 3 RCT investigates if dysphagia-optimised intensity-modulated radiotherapy (IMRT) reduces radiation dose to the dysphagia and aspiration related structures and improves swallowing function compared with standard IMRT. #hncsm.
1
28
53
At the end of a challenging year, @TheLancetOncol would like to thank health-care workers worldwide for their huge contribution to our health this year. Thanks also to our fantastic authors & reviewers for their support of our journal. We look forward to working with you in 2021!
1
14
53
NOW OF: In the OUTBACK ph 3 trial of adjuvant chemotherapy after chemoradiotherapy for locally advanced cervical cancer, 5-year OS was 72% (95% CI 67-76) w/ adjuvant chemotherapy group and 71% (66=75) w/o (HR 0·90, 95% CI 0·70-1·17; p=0·81). #gyncsm.
0
27
48
Today is #WorldCancerDay: we support the global call to close the gap in #cancercare .#CloseTheCareGap. How can we close the gap to deliver sustainable #childhoodcancer care worldwide? Watch the #LancetWebinar on our #childhoodcancer Commission:
1
19
48
Oh dear, here we go again. Cancer de-prioritisation is not the answer.
Covid: Urgent cancer ops cancelled in parts of London
0
17
50
Leading oncologists sound the alarm on cancer care crisis in the UK, and outline radical yet sustainable National Cancer Plan in @TheLancetOncol.
1
24
49
Being presented at @ASCO #GU25 ⬇️. Overall survival & QOL results from ENZA-p:.[177Lu]Lu-PSMA-617 plus enzalutamide vs enzalutamide in metastatic castration-resistant #prostatecancer. @drlouiseemmett @Prof_IanD @DrMHofman @MartinStockler @ANZUPtrials.
2
31
51
ICYMI: The KEYNOTE-585 double-blind, randomised phase 3 trial assesses antitumour activity of neoadjuvant and adjuvant pembrolizumab plus chemotherapy in patients with locally advanced resectable gastric or gastro-oesophageal adenocarcinoma.
1
19
49
Now in the July issue: Stereotactic body #radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
0
12
49
Read a NEW Comment by Ben Anderson and colleagues about the @WHO Global Breast Cancer Initiative #GBCI launching TODAY on #InternationalWomensDay #IWD2021 #breastcancer #bcsm
0
29
46
NEW: In the LEAP-002 ph 3 RCT of lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma, lenvatinib plus pembrolizumab did not meet prespecified significance for improved OS and PFS. #hccsm.
2
17
49
The APRIL issue of @TheLancetOncol is online: ..This issue includes our new #MedicalImaging and #NuclearMedicine Commission, plus articles on #headandneckcancer, #cervicalcancer, #lymphoma, #breastcancer, #ovariancancer & more!
0
19
47
Today is International #ChildhoodCancerDay 2021. Alongside @TheLancetHaem &@LancetChildAdol, we share our editors’ highlights on the theme: better survival is achievable. Explore the thread👇.#throughourhands #childhoodcancer #pedcsm.
1
25
49
Online First:. #Palliative #radiotherapy versus best supportive care in patients with painful #hepaticcancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study. #radonc.
0
20
47
Article online: 10-year follow-up of a #trial comparing axillary #dissection with no axillary dissection for #breastcancer & sentinel-node #micrometastases—the IBCSG 23-01 trial
0
42
46
Online First:. Personal View: Interchangeability of immune checkpoint inhibitors: an urgent need for action. #ImmuneCheckpointInhibitors.
0
19
47
Online first: Population-based study estimates that between 2018 and 2040, the number of people requiring #chemotherapy will rise by ~50% & ~100,000 cancer physicians will be needed to deliver optimal services worldwide
0
43
47
NEW: RANO propose a set of criteria for response assessment based on amino acid PET imaging in clinical trials enrolling participants with diffuse gliomas.
2
22
45
Without additional investment 11 million children are expected to die from cancer between now & 2050, but sustainable care for children with cancer is affordable & achievable in all countries: new @TheLancetOncol Commission #FutureChild #Childhoodcancer
1
40
44
Inspiration for the August cover art:. First-in-human trial of #imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade #neuroendocrinetumours of the lung and prostate #NeuroendocrineTumors #SCLC
2
16
45
Online first: NRG Oncology/RTOG 1010 – #Trastuzumab with trimodality treatment for #oesophageal adenocarcinoma with HER2 overexpression: a multicentre, randomised, phase 3 trial.
0
19
45
Online first: The NADIM study: #Neoadjuvant #chemotherapy and #nivolumab in resectable non-small-cell #lungcancer: an open-label, multicentre, single-arm, phase 2 trial #NSCLC #lcsm
1
24
46
NEW: In the ENZAMET ph 3 trial of testosterone suppression plus enzalutamide or antiandrogen therapy for metastatic hormone-sensitive prostate cancer, 5-year OS was 57% (0·53–0·61) in the control group and 67% (0·63–0·70) in the enzalutamide group. #pcsm.
0
25
47
Online first: ZUMA-5 - #Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin #lymphoma: a single-arm, multicentre, phase 2 trial .#CARTcell #lymsm.
1
20
43
Our February issue is live. Read it here: .With articles on #NSCLC, #radiotherapy, #bladdercancer, #patientreportedoutcomes, #kidneycancer, #prostatecancer, #oesophagealcancer, #COVID19 & more
2
21
44
Today is World Blood Cancer Day #WBCD 2019! In this joint thread with @TheLancetHaem, we share some of our editors’ highlights, all free to read with reg until June 4th #OncoAlert #BloodCancer #HemOnc #HaemOnc
3
31
44
The importance and extraordinary demand for cancer surgery cannot be overstated; a new Lancet Oncology Commission sets out a roadmap to improve access, delivery, and care for every patient. 📌
3
23
43
Our June issue is now online! READ it here: With articles on astrocytoma, #colorectalcancer #CRC, #skincancer, #breastcancer, #NSCLC #lungcancer, #multiplemyeloma, #lymphoma, the #COVIDVaccine in patients with #cancer, & much more
4
16
42